Mechanisms of Stroke in Atrial Fibrillation

https://doi.org/10.1016/j.ccep.2013.10.007Get rights and content

Section snippets

Key points

  • Atrial fibrillation (AF) is the most common form of arrhythmia and its prevalence is projected to increase. The risk of stroke in patients with AF is increased by 5-fold, and strokes in association with AF are more often fatal, disabling, and associated with greater morbidity and recurrence than other causes of stroke.

  • The causes of thrombus formation in the context of AF are multifactorial and include changes in flow, atrial anatomy, prothrombotic alterations in blood constituents, and

Pathophysiology of thrombus formation

Despite gaps in our knowledge, it is now clear that the pathogenesis of thrombus formation in AF is a multifactorial process that includes not only stasis in a poorly contractile left atrium, but also the presence of a prothrombotic or hypercoagulable state.6 As reflected in Virchow triad, thrombogenesis in patients with AF occurs as a result of endocardial damage, blood stasis, and abnormal regulation of blood constituents responsible for clot formation and fibrinolysis (Fig. 1).

Risk stratification in patients with nonvalvular AF

Traditionally, the CHADS2 score (congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, and prior stroke [2 points]) has been used to identify patients with AF who would benefit from anticoagulation (Table 1). US practice guidelines suggest the use of antithrombotics for patients with nonvalvular AF and a CHADS2 scores ≥2, whereas those with CHADS2 score of 0 are at low risk of thromboembolism and should be treated with aspirin or no antithrombotic therapy. For patients at

Stroke prevention: the expanding role for anticoagulation

Anticoagulation is the only therapy in AF management that has thus far been shown to reduce AF-related mortality. Available options for prevention of thromboembolism in patients with AF include anticoagulant and antiplatelet agents. Warfarin decreases the risk of stroke by 67% compared with placebo,34 and even more when assessed by on-treatment analysis.35 Aspirin decreases the risk by 20% compared with placebo, and warfarin reduces stroke by about 40% compared with aspirin.36 Unfortunately,

Achievement of sinus rhythm after AF ablation: what is the residual risk of stroke?

Catheter ablation is an effective treatment strategy for the maintenance of sinus rhythm in patients with drug-refractory, symptomatic AF.44 Its role in the reduction of stroke and mortality, however, remains less certain. Several large studies—most notably the AFFIRM (Atrial Fibrillation Follow-up Investigation of Rhythm Management) trial—have examined the effectiveness of a rate control versus a rhythm control strategy and have established that anti-arrhythmic drugs (AADs) offer no mortality

Summary

AF is the most common arrhythmia in clinical practice and is associated with substantial morbidity and mortality, primarily because of thromboembolic stroke. Better understanding of the complex mechanisms behind thromboembolism in patients with AF, together with more inclusive risk stratification models, can help identify those patients at elevated risk for stroke or hemorrhage, and perhaps most importantly distinguish those at lowest stroke risk in whom anticoagulation can be safely deferred.

First page preview

First page preview
Click to open first page preview

References (61)

  • G.Y. Lip et al.

    Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on atrial fibrillation

    Chest

    (2010)
  • B.F. Gage et al.

    Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF)

    Am Heart J

    (2006)
  • J. Carlsson et al.

    Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation: the Strategies of Treatment of Atrial Fibrillation (STAF) study

    J Am Coll Cardiol

    (2003)
  • P. Dorian et al.

    The impairment of health-related quality of life in patients with intermittent atrial fibrillation: implications for the assessment of investigational therapy

    J Am Coll Cardiol

    (2000)
  • C. Pappone et al.

    A randomized trial of circumferential pulmonary vein ablation versus antiarrhythmic drug therapy in paroxysmal atrial fibrillation: the APAF Study

    J Am Coll Cardiol

    (2006)
  • K. Nademanee et al.

    Clinical outcomes of catheter substrate ablation for high-risk patients with atrial fibrillation

    J Am Coll Cardiol

    (2008)
  • S. Themistoclakis et al.

    The risk of thromboembolism and need for oral anticoagulation after successful atrial fibrillation ablation

    J Am Coll Cardiol

    (2010)
  • Y. Miyasaka et al.

    Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence

    Circulation

    (2006)
  • F.W. Verheugt

    Novel oral anticoagulants to prevent stroke in atrial fibrillation

    Nat Rev Cardiol

    (2010)
  • P.A. Wolf et al.

    Atrial fibrillation: a major contributor to stroke in the elderly. The Framingham Study

    Arch Intern Med

    (1987)
  • European Heart Rhythm Association et al.

    Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC)

    Eur Heart J

    (2010)
  • J.J. Caro

    An economic model of stroke in atrial fibrillation: the cost of suboptimal oral anticoagulation

    Am J Manag Care

    (2004)
  • N. Masawa et al.

    Diagnosis of cardiac thrombosis in patients with atrial fibrillation in the absence of macroscopically visible thrombi

    Virchows Arch A Pathol Anat Histopathol

    (1993)
  • F. Marin et al.

    Is thrombogenesis in atrial fibrillation related to matrix metalloproteinase-1 and its inhibitor, TIMP-1?

    Stroke

    (2003)
  • M.R. Di Tullio et al.

    Left atrial size and the risk of ischemic stroke in an ethnically mixed population

    Stroke

    (1999)
  • C. Gustafsson et al.

    Coagulation factors and the increased risk of stroke in nonvalvular atrial fibrillation

    Stroke

    (1990)
  • G.Y. Lip et al.

    Increased markers of thrombogenesis in chronic atrial fibrillation: effects of warfarin treatment

    Br Heart J

    (1995)
  • H. Asakura et al.

    Prothrombin fragment F1 + 2 and thrombin-antithrombin III complex are useful markers of the hypercoagulable state in atrial fibrillation

    Blood Coagul Fibrinolysis

    (1992)
  • M. Soncini et al.

    Hypercoagulability and chronic atrial fibrillation: the role of markers of thrombin generation

    Minerva Med

    (1997)
  • R.M. Heppell et al.

    Haemostatic and haemodynamic abnormalities associated with left atrial thrombosis in non-rheumatic atrial fibrillation

    Heart

    (1997)
  • Cited by (14)

    • A literature embedding model for cardiovascular disease prediction using risk factors, symptoms, and genotype information

      2023, Expert Systems with Applications
      Citation Excerpt :

      We found that all 10 genes for stroke, 10 genes for atrial fibrillation, and 8 genes for ventricular fibrillation were accurately identified, as shown in Table 5. In Table 5.1, several CVD-related genes were correctly identified, as they are known to be associated with a risk of stroke: HMGA1 (heart attack) (De Rosa et al., 2017; Witt et al., 2006), RAB7A (chronic Q fever) (González-Quijada et al., 2015; Jansen et al., 2019), TMPRSS9 (atrial fibrillation) (Castellano et al., 2014; Hsieh et al., 2019), DNAL4 (hypertension) (Y. Meng et al., 2017; Wajngarten & Silva, 2019), and GABRB3 (epilepsy) (Chang et al., 2014; Tanaka et al., 2012). REG3A (Sands Madison et al., 2021), CCR6 (Wan & Murphy, 2011), TRIM39 (Suzuki et al., 2016), FBXO40 (Liu et al., 2020), and ABHD14B (Liu et al., 2016) are involved in immune responses to atherosclerosis which can lead to stroke (Wan & Murphy, 2011).

    • Left atrial dilatation is associated with severe ischemic stroke in men with non-valvular atrial fibrillation

      2015, Journal of the Neurological Sciences
      Citation Excerpt :

      In patients with NVAF, the CHA2DS2-VASc risk factors are known to be associated with developing ischemic stroke rather than single causal factors [22]. Virchow's triad, including atrial tissue damage, hypercoagulable state, and blood stasis, was proposed to play a role in the pathophysiologic mechanism of thrombogenesis in AF [8,9]. Blood stasis in AF occurs not only because of loss of atrial systole but also in relation to left atrial dilatation [8].

    • Prevention and Management of Cardiovascular and Metabolic Disease: Diet, Physical Activity and Healthy Aging

      2023, Prevention and Management of Cardiovascular and Metabolic Disease: Diet, Physical Activity and Healthy Aging
    View all citing articles on Scopus

    Financial Disclosure: The authors have no financial disclosures or relationships to report.

    View full text